~~<i id='9134AC50B7'><strike id='9134AC50B7'><tt id='9134AC50B7'><pre id='9134AC50B7'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

comprehensive

author：knowledge 2025-09-27 10:03:21 - browse：85793

The chief executive of the country’s biggest hospital chain said Thursday that labor costs are now lower as a percent of revenue than they were before the pandemic.

“And again, that’s in the face of a very difficult labor market,” HCA Healthcare CEO Sam Hazen noted on the company’s second quarter earnings call. Health care providers and insurers are in the full swing of releasing their second-quarter earnings, and HCA tends to outperform its peers.

Hospitals struggled with the high cost of nurses throughout the Covid-19 pandemic, but HCA on Thursday said several of its workforce initiatives are paying off.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban
Next article： The problems with dementia villages

hotspot

focus

hotspot

explore

focus

DonorlungstreatedwithenzymestochangetheirbloodtypeareshowninanexvivolungperfusionmachineinthelabofMa

WSS

Health tech investors get more selective as pandemic boom fades

Altering the blood type of lungs raises potential for universal organs for transplants

Roche acquires Telavant from Roivant, adding experimental IBD treatment

FDA approves first new drug developed for postpartum depression

Roivant's CEO is a star, but biotech's black hole persists

Sea level rise could wash away turtle breeding grounds around the world, researchers say

entertainment

comprehensive

hotspot

Bright Health sells Medicare Advantage business to Molina

Study on Amgen’s bispecific immunotherapy produces positive data

Moonlake's readout produced a cash windfall. Risks remain

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Wildfire smoke exposes gaps in outdoor worker protections

Roche drug slashes death risk in early

At least 13 dead in Texas as scorching temps continue

UnitedHealth, Optum discontinue NaviHealth name

Walensky prepares to leave CDC — and Congress — behind

Questions loom on AstraZeneca cancer drug as safety concerns ebb

focus

STAT Readout Newsletter: Biotech news today

Health tech investors get more selective as pandemic boom fades

Questions loom on AstraZeneca cancer drug as safety concerns ebb

A public health expert passes on football's full body collisions for youths

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

hotspot

explore

explore

focus